[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019012331A - Metodo para producir proteinas de doble funcion y sus derivados. - Google Patents

Metodo para producir proteinas de doble funcion y sus derivados.

Info

Publication number
MX2019012331A
MX2019012331A MX2019012331A MX2019012331A MX2019012331A MX 2019012331 A MX2019012331 A MX 2019012331A MX 2019012331 A MX2019012331 A MX 2019012331A MX 2019012331 A MX2019012331 A MX 2019012331A MX 2019012331 A MX2019012331 A MX 2019012331A
Authority
MX
Mexico
Prior art keywords
dual function
derivatives
protein
function proteins
producing dual
Prior art date
Application number
MX2019012331A
Other languages
English (en)
Inventor
Hyun Choi Byung
Hong Kim Ki
Hwan Kim Jun
Young Song Moo
Gyun KIM Jong
Hwan Lim In
Young Park Jun
Hyoung Lee Jin
Yong Jo Hae
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2019012331A publication Critical patent/MX2019012331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee un método para producir una proteína de doble función que comprende una proteína biológicamente activa y una proteína mutante FGF21. El método permite la producción estable de una proteína objetivo previniendo efectivamente la descomposición de la proteína objetivo y, por lo tanto, tiene un alto potencial para uso comercial.
MX2019012331A 2017-04-21 2018-04-20 Metodo para producir proteinas de doble funcion y sus derivados. MX2019012331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051758 2017-04-21
PCT/KR2018/004599 WO2018194413A1 (en) 2017-04-21 2018-04-20 Method for producing dual function proteins and its derivatives

Publications (1)

Publication Number Publication Date
MX2019012331A true MX2019012331A (es) 2020-01-23

Family

ID=63856679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012331A MX2019012331A (es) 2017-04-21 2018-04-20 Metodo para producir proteinas de doble funcion y sus derivados.

Country Status (14)

Country Link
US (2) US11560416B2 (es)
EP (1) EP3612637A4 (es)
JP (2) JP7191850B2 (es)
KR (1) KR102664780B1 (es)
CN (1) CN110709520B (es)
AU (2) AU2018256256B2 (es)
BR (1) BR112019021923A2 (es)
CA (1) CA3060934A1 (es)
CL (1) CL2019002848A1 (es)
EA (1) EA201992516A1 (es)
MX (1) MX2019012331A (es)
PH (1) PH12019550221A1 (es)
WO (1) WO2018194413A1 (es)
ZA (1) ZA201907115B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11179440B2 (en) 2016-11-10 2021-11-23 Yuhan Corporation Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
CN113583142A (zh) * 2021-08-20 2021-11-02 赣江中药创新中心 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
EP1735340A2 (en) 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
JP2009534424A (ja) 2006-04-20 2009-09-24 アムジエン・インコーポレーテツド Ｇｌｐ−１化合物／グルカゴン抗体組成物
HUE035243T2 (hu) * 2007-02-23 2018-05-02 Sk Chemicals Co Ltd Eljárás VIII. faktor és származékainak elõállítására és tisztítására
JP5577243B2 (ja) 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
EP2185178B1 (en) 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CL2009000912A1 (es) 2008-04-17 2009-10-09 Metodo para la produccion de bmp-2 que comprende; cultivar una celula huesped que comprende la molecula de adn que codifica bmp-2 en medio de cultivo en presencia de hierro, un compuesto polianionico y piridoxal; recuperar la proteina de interes donde la celula huesped se cultiva en bioreactor.
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
RS65153B1 (sr) 2009-05-05 2024-02-29 Amgen Inc Fgf21 mutanti i njihove upotrebe
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
CN102802657A (zh) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN101993496B (zh) 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2526117B1 (en) 2010-01-22 2015-05-06 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
CN103124562A (zh) 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
CN103415300B (zh) 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
JP6077461B2 (ja) 2011-01-04 2017-02-08 ウニヴェルズィテート チューリッヒ アルツハイマー病の予防又は治療のためのｉｌ−１２及び／又はｉｌ−２３のモジュレーター
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
JP2014526441A (ja) 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
PE20150648A1 (es) 2012-09-07 2015-05-25 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
US11959196B2 (en) 2015-07-06 2024-04-16 Pbi Performance Products, Inc. Phosphonated PBI fiber
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
US11179440B2 (en) 2016-11-10 2021-11-23 Yuhan Corporation Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
EP3596130A4 (en) 2017-03-14 2020-12-30 Sunshine Lake Pharma Co., Ltd. DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.

Also Published As

Publication number Publication date
PH12019550221A1 (en) 2021-04-05
JP2023036638A (ja) 2023-03-14
US11560416B2 (en) 2023-01-24
US20210188936A1 (en) 2021-06-24
WO2018194413A1 (en) 2018-10-25
RU2019137213A3 (es) 2021-08-13
EP3612637A1 (en) 2020-02-26
CL2019002848A1 (es) 2020-03-13
AU2018256256B2 (en) 2023-02-23
EP3612637A4 (en) 2021-01-27
JP7191850B2 (ja) 2022-12-19
AU2018256256A1 (en) 2019-11-21
EA201992516A1 (ru) 2020-04-09
ZA201907115B (en) 2021-01-27
BR112019021923A2 (pt) 2020-06-02
US20230212249A1 (en) 2023-07-06
RU2019137213A (ru) 2021-05-21
KR20180118550A (ko) 2018-10-31
CN110709520B (zh) 2024-04-05
AU2023203121A1 (en) 2023-06-15
JP2020517265A (ja) 2020-06-18
CN110709520A (zh) 2020-01-17
KR102664780B1 (ko) 2024-05-13
CA3060934A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
PH12019550221A1 (en) Method for producing dual function proteins and its derivatives
MX2020001903A (es) Novedoso polipeptido y procedimiento de produccion de imp mediante el uso del mismo.
AU2018338314A1 (en) Protein degraders and uses thereof
EP4338802A3 (en) Tyk2 inhibitors, uses, and methods for production thereof
MX2021006564A (es) Sistemas activos dinamicos acromosomicos.
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
MX2019010769A (es) Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
MX2019008546A (es) Usos terapeuticos de un polvo de insectos.
MY195550A (en) Antibody Formulation
CA190044S (en) Portion of an insole
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
MX2020011740A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso.
MX2021003070A (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino.
SA520411112B1 (ar) عملية محسّنة لتحضير مشتقات أمينو بيريميدين
WO2020128870A3 (en) Methods of producing heterodimeric antibodies
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
WO2018211324A8 (en) Prodrugs for the treatment of disease
CA3088406A1 (en) Methods and systems of producing pharmaceutical grade lantibiotics
EP4218748A3 (en) Bmp-mimetics
SG11201900713XA (en) Method of preparing coal ash
CA3156366A1 (en) PROCESS FOR THE PRODUCTION OF ALKANESULPHONIC ACIDS
WO2019014286A3 (en) IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF
MX2020000752A (es) Combinaciones farmaceuticas que comprenden un anticuerpo anti bst-1 y un analogo de citidina.
WO2019004702A3 (ko) 기능성 감미료의 제조방법